Literature DB >> 7536200

Concentrations, release, and disposal of insulin-like growth factor (IGF)-binding proteins (IGFBP), IGF-I, and growth hormone in different vascular beds in patients with cirrhosis.

S Møller1, A Juul, U Becker, A Flyvbjerg, N E Skakkebaek, J H Henriksen.   

Abstract

The liver is thought to be the major source of circulating insulin-like growth factor (IGF-I) and IGF-binding protein-1 (IGFBP-1), whereas the primary production site of circulating IGFBP-3 remains unknown. As other tissues may contribute to the circulating pool of IGF-I and IGFBP, the aim of the present study was to assess the hepatic and renal arterio-venous difference and production rates of IGF-I, IGFBP-1, IGFBP-3, and GH in cirrhotic patients (n = 22) and matched control subjects (n = 27). IGFBP-1 and -3, IGF-I, and GH levels were measured by RIA in hepatic, renal, and peripheral veins and in the femoral artery. Levels of IGFBP-1 to -4 were additionally determined by Western ligand blotting. Hepatic venous IGFBP-1 was significantly increased in the cirrhotic patients (mean +/- SEM, 33.6 +/- 9.1 vs. 10.4 +/- 1.9 micrograms/L; P < 0.001), and arterio-renal-venous extraction was significant in both patients (6 +/- 2%; P < 0.01) and controls (11 +/- 1%; P < 0.001). Conversely, IGFBP-3 was decreased in the cirrhotic patients (1265 +/- 149 vs. 2712 +/- 137 micrograms/L; P < 0.001). IGFBP-3 correlated significantly with the wedged hepatic venous pressure (r = -0.49; P < 0.05), serum aspartate aminotransferase (r = -0.66; P < 0.01), serum bilirubin (r = -0.65; P < 0.01), serum albumin (r = 0.64; P < 0.01), and the Child score (r = -0.57; P < 0.01). IGF-I was significantly lower in the cirrhotics (57 +/- 10 vs. 143 +/- 11 micrograms/L; P < 0.001). No significant IGFBP-3 proteolysis was demonstrated in cirrhotics or controls. No significant differences were found in the values obtained simultaneously from hepatic, renal, and brachial veins or femoral artery, which suggests that no major net production or release of IGFBP-3 or IGF-I occurs in these tissues. No differences in IGFBP-2 or IGFBP-4 determined by Western ligan blot were found between patients and controls. The IGF-I concentrations correlated significantly with parameters of biochemical liver function. Basal GH concentrations were significantly higher in the cirrhotics (1.19 +/- 0.13 vs. 0.58 +/- 0.08 micrograms/L; P < 0.001). A significant hepatic disposal of GH was found in the patients (P < 0.05) and controls (P < 0.001).(ABSTRACT TRUNCATED AT 400 WORDS)

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7536200     DOI: 10.1210/jcem.80.4.7536200

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  12 in total

1.  Low IGF-I levels are often uncoupled with elevated GH levels in catabolic conditions.

Authors:  L Gianotti; F Broglio; G Aimaretti; E Arvat; S Colombo; M Di Summa; G Gallioli; G Pittoni; E Sardo; M Stella; M Zanello; C Miola; E Ghigo
Journal:  J Endocrinol Invest       Date:  1998-02       Impact factor: 4.256

2.  Role of insulin-like growth factor-I in primary osteoporosis: a correlative study.

Authors:  L Calò; R Castrignano; P A Davis; G Carraro; E Pagnin; S Giannini; A Semplicini; A D'Angelo
Journal:  J Endocrinol Invest       Date:  2000-04       Impact factor: 4.256

3.  Disturbed synthesis of insulinlike growth factor I and its binding proteins may influence renal function changes in liver cirrhosis.

Authors:  C M Fernández-Rodriguez; I Prada; A Andrade; M Moreiras; R Guitián; R Aller; J L Lledó; G Cacho; J Quiroga; J Prieto
Journal:  Dig Dis Sci       Date:  2001-06       Impact factor: 3.199

4.  Relation of insulin-like growth factor-1 and insulin-like growth factor binding protein-3 levels to growth retardation in extrahepatic portal vein obstruction.

Authors:  Lalit Nihal; Mukta R Bapat; Pravin Rathi; Nalini S Shah; Anjana Karvat; Philip Abraham; Shobna J Bhatia
Journal:  Hepatol Int       Date:  2008-09-20       Impact factor: 6.047

Review 5.  Hepatitis C virus coinfection as a risk factor for osteoporosis and fracture.

Authors:  Roger Bedimo; Naim M Maalouf; Vincent Lo Re
Journal:  Curr Opin HIV AIDS       Date:  2016-05       Impact factor: 4.283

6.  Serum prolidase and IGF-1 as non-invasive markers of hepatic fibrosis during four different periods after bile-duct ligation in rats.

Authors:  Orhan Tarçin; Nursal Gedik; Berna Karakoyun; Veysel Tahan; Gagan Sood; Ciğdem Celikel; Nurdan Tözün
Journal:  Dig Dis Sci       Date:  2007-11-13       Impact factor: 3.199

7.  Circulating insulin-like growth factor-binding protein 3 as prognostic biomarker in liver cirrhosis.

Authors:  Carina Gabriela Correa; Bruno da Silveira Colombo; Marcelo Fernando Ronsoni; Pedro Eduardo Soares E Silva; Leonardo Fayad; Telma Erotides Silva; Letícia Muraro Wildner; Maria Luiza Bazzo; Esther Buzaglo Dantas-Correa; Janaína Luz Narciso-Schiavon; Leonardo de Lucca Schiavon
Journal:  World J Hepatol       Date:  2016-06-18

8.  Clinical significance of serum IGF-I, IGF-II and IGFBP-3 in liver cirrhosis.

Authors:  Yun-Lin Wu; Jing Ye; Shu Zhang; Jie Zhong; Rong-Ping Xi
Journal:  World J Gastroenterol       Date:  2004-09-15       Impact factor: 5.742

9.  Expression of insulin-like growth factor 1 and insulin-like growth factor 1 receptor and its intervention by interleukin-10 in experimental hepatic fibrosis.

Authors:  Xiao-Zhong Wang; Zhi-Xin Chen; Li-Juan Zhang; Yun-Xin Chen; Dan Li; Feng-Lin Chen; Yue-Hong Huang
Journal:  World J Gastroenterol       Date:  2003-06       Impact factor: 5.742

10.  Postoperative Insulin-Like Growth Factor 1 Levels Reflect the Graft's Function and Predict Survival after Liver Transplantation.

Authors:  Daniele Nicolini; Federico Mocchegiani; Gioia Palmonella; Martina Coletta; Marina Brugia; Roberto Montalti; Giammarco Fava; Augusto Taccaliti; Andrea Risaliti; Marco Vivarelli
Journal:  PLoS One       Date:  2015-07-17       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.